ASX Share rice
Tue 18 May 2021 - 12:37:pm (Sydney)

NEU Share Price

NEUREN PHARMACEUTICALS LIMITEDNEUPharmaceuticals, Biotechnology & Life Sciences

NEU Company Information

Name:

Neuren Pharmaceuticals Limited

Sector:

Healthcare

Industry:

Biotechnology

GIC Industry:

Pharmaceuticals

GIC Sub Industry:

Pharmaceuticals

Address:

697 Burke Road Camberwell VIC Australia 3124

Phone:

61 3 9092 0480

Chief Exec. Officer:

Mr. Jonathan Charles Pilcher A.C.A., B.Sc., BSc (Hons), ACA

CFO & Company Sec.:

Ms. Lauren Frazer C.A.

Chief Science Officer:

Mr. Lawrence Glass

Company Overview:

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, and Pitt Hopkins syndromes. In addition, it provides development services; and holds loan funded shares. Neuren Pharmaceuticals Limited was incorporated in 2001 and is based in Camberwell, Australia.

NEU Share Price Information

Shares Issued:

117.61M

Market Capitalisation:

$144.66M

Revenue (TTM):

$817K

Revenue Per Share (TTM):

$0.01

Earnings per Share:

$-0.007

Operating Margin (TTM):

$-10.66

Return On Assets (TTM):

$-0.28

Return On Equity (TTM):

$-0.48

Quarterly Revenue Growth (YOY):

0.549

Gross Profit(TTM):

$-6,946,000

Diluted Earnings Per Share (TTM):

$-0.086

NEU CashFlow Statement

CashFlow Date:

2020-12-31

Investments:

$-6,000

Change To Liabilities:

$194K

Total Cashflow From Investing Activities:

$-6,000

Net Income:

$-9,193,000

Total Cash From Operating Activities:

$-8,078,000

Depreciation:

$6K

Change To Account Receivables:

$-203,000

Sale Purchase Of Stock:

$-1,075,000

Capital Expenditures:

$6K

NEU Income Statement

Income Date:

2020-12-31

Income Before Tax:

$-9,193,000

Net Income:

$-9,193,000

Operating Income:

$-9,526,000

Total Revenue:

$147K

NEU Balance Sheet

Balance Sheet Date:

2020-12-31

Total Liabilities:

$753K

Total Stockholder Equity:

$24.20M

Total Assets:

$24.95M

Common Stock:

$145.57M

Retained Earnings:

$-111,083,000

Cash:

$24.19M

Total Current Liabilities:

$753K

Property - Plant & Equipment:

$10K

Net Tangible Assets:

$24.20M

Total Current Assets:

$24.94M

Net Receivables:

$755K

Short-Term Investments:

$10K

Accounts Payable:

$167K

Short-Term Investments:

$10

Non Current Liabilities Total:

$0

NEU Share Price History

NEU News

01 Mar, 2021
We can readily understand why investors are attracted to unprofitable companies. For example, although...
30 Nov, 2020
Every investor in Neuren Pharmaceuticals Limited (ASX:NEU) should be aware of the most powerful shareholder groups...
03 Jun, 2020
Whilst it may not be a huge deal, we thought it was good to see that the Neuren Pharmaceuticals Limited (ASX:NEU...
19 May, 2020
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...